Provided by Tiger Trade Technology Pte. Ltd.

Glaukos

164.19
+5.643.56%
Post-market: 164.190.00000.00%19:54 EDT
Volume:947.09K
Turnover:154.98M
Market Cap:9.68B
PE:-50.59
High:165.65
Open:158.31
Low:157.29
Close:158.55
52wk High:191.62
52wk Low:73.16
Shares:58.98M
Float Shares:56.44M
Volume Ratio:1.00
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2456
EPS(LYR):-3.2819
ROE:-25.98%
ROA:-5.18%
PB:14.19
PE(LYR):-50.03

Loading ...

Glaukos Q2 Adjusted Loss Narrows, Revenue Rises

MT Newswires Live
·
Jul 30

GUIDANCE: (GKOS) Glaukos Expects 2026 Net Sales Range $680M-$700M, vs. FactSet Est of $630M

MT Newswires Live
·
Jul 30

Glaukos Q2 Sales Jump 50%; Raises Net Sales Forecast

Reuters
·
Jul 30

Glaukos Q2 Sales USD 185.6 Million Vs. IBES Estimate USD 150.9 Million

Reuters
·
Jul 30

Glaukos Q2 Adj. EPS $(0.14) Beats $(0.22) Estimate, Sales $185.610M Beat $150.978M Estimate

Benzinga Earnings
·
Jul 30

Movement Alert|Glaukos Rises 5.05% in After-Hours Trading, Pipeline Milestone and Earnings Catalyst Drive Momentum

Market Focus
·
Jul 30

Movement Alert|Glaukos Rises 5.07% in Regular Trading, Pipeline Milestone and Earnings Optimism Fuel Rally

Market Focus
·
Jul 30

Glaukos Coverage Assumed by UBS at Neutral vs Previous Rating of Buy

Dow Jones
·
Jul 29

UBS Downgrades Glaukos to Neutral From Buy, $150 Price Target

MT Newswires Live
·
Jul 28

Stifel Nicolaus Sticks to Their Buy Rating for Glaukos (GKOS)

TIPRANKS
·
Jul 28

Glaukos Completes Enrollment in 510(k) Pivotal Study of Preserflo MicroShunt for Advanced Glaucoma Patients

Reuters
·
Jul 27

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for Preserflo™ Microshunt

THOMSON REUTERS
·
Jul 27

Earning Preview: Glaukos revenue is expected to increase by 30.68% this quarter, and institutional views are bullish

Earnings Agent
·
Jul 22

Glaukos CFO Alex R. Thurman Disposes of USD 1.6 Million in Common Shares

Reuters
·
Jul 22

Glaukos (GKOS) Could Be 1% Undervalued After Its Pipeline Growth Narrative

Simply Wall St.
·
Jul 17

Glaukos is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 17

Truist Adjusts Price Target on Glaukos to $180 From $160, Maintains Buy Rating

MT Newswires Live
·
Jul 16

Mobia Medical Names Reza Zadno to Board as Independent Director

Reuters
·
Jul 16

Glaukos CFO Alex R. Thurman Sells 10,000 Shares for $1.55 Million

Reuters
·
Jul 14

Glaukos Chief Development Officer Tomas Navratil Disposes of 716 Shares for $99,571.96

Reuters
·
Jul 09